XML 23 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2018
Jul. 31, 2017
Jul. 31, 2016
OPERATING ACTIVITIES      
Net income $ 5,199 $ 9,641 $ 25,358
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 22,801 21,704 20,535
Deferred income taxes 6,174 (2,329) 3,809
Provision for doubtful accounts receivable 2,199 [1] 686 [1] 1,519
Gain on sale of interest in Fabrix Systems Ltd. (1,086)
Gain on sale of member interest in Visa Europe Ltd. (7,476)
Net realized loss (gain) from marketable securities 16 (323) (543)
Interest in the equity of investments (9) (356) 362
Stock-based compensation 3,581 3,740 2,680
Change in assets and liabilities:      
Restricted cash and cash equivalents (13,500) (17,702) (22,548)
Trade accounts receivable (6,668) (17,972) 616
Prepaid expenses, other current assets and other assets (18,889) (4,856) 8,372
Trade accounts payable, accrued expenses, other current liabilities and other liabilities 12,769 17,344 (10,099)
Customer deposits 14,660 18,980 25,344
Deferred revenue (21,439) (9,543) 2,211
Net cash provided by operating activities 6,894 19,014 49,054
INVESTING ACTIVITIES      
Capital expenditures (20,567) (22,949) (18,370)
Proceeds from sale of interest in Straight Path IP Group Holding, Inc. 6,000    
Purchase of IP interest from Straight Path Communications Inc. (6,000)
Payment for acquisition, net of cash acquired (1,827)
Proceeds from sale of interest in Fabrix Systems Ltd. 9,557
Proceeds from sale of member interest in Visa Europe Ltd (53) 5,597
Cash used for purchase of investments (9,438) (2,002)
Proceeds from sales and redemptions of investments 15 634
Purchases of marketable securities (22,523) (53,402) (46,909)
Proceeds from maturities and sales of marketable securities 41,502 47,996 35,011
Net cash used in investing activities (1,641) (39,605) (16,482)
FINANCING ACTIVITIES      
Dividends paid (13,941) (17,874) (17,358)
Distributions to noncontrolling interests (1,040) (1,482) (1,834)
Sales of Class B common stock to Howard S. Jonas   24,930  
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas 1,000
Proceeds from sale of member interests in CS Pharma Holdings, LLC 1,250 8,750
Cash deconsolidated as a result of spin-off (9,287) (6,381)
Proceeds from sale of Zedge equity prior to the spin-off 374
Proceeds from exercise of stock options 836
Proceeds from borrowings under revolving credit facility 22,320
Repayments of borrowings including revolving credit facility (22,320) (6,353)
Repurchases of Class B common stock (2,293) (1,838) (4,773)
Net cash (used in) provided by financing activities (26,561) 6,822 (27,575)
Effect of exchange rate changes on cash and cash equivalents (771) 292 (5,821)
Net decrease in cash and cash equivalents (22,079) (13,477) (824)
Cash and cash equivalents at beginning of year, including $5,716, $5,536 and $571 held for sale at July 31, 2017, 2016 and 2015, respectively (see Note 3) 96,060 109,537 110,361
Cash and cash equivalents at end of year, including $5,892, $5,716 and $5,536 held for sale at July 31, 2018, 2017 and 2016, respectively (see Note 3) 73,981 96,060 109,537
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      
Cash payments made for interest 94 288 345
Cash payments made for income taxes 192 576 779
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES      
Net assets excluding cash and cash equivalents deconsolidated as a result of spin-off $ (105,632)   (4,681)
Reclassification of liability for member interests in CS Pharma Holdings, LLC   $ 8,750  
Shares of Visa Inc. Series C preferred stock received from sale of member interest in Visa Europe Ltd.     $ 1,580
[1] Includes allowance for doubtful accounts of $2.2 million and $2.6 million held for sale at July 31, 2018 and 2017, respectively (see Note 3)